ClinicalTrials.gov
ClinicalTrials.gov Menu

Warfarin - How Good Are we at Maintaining Target Range ?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01081327
Recruitment Status : Unknown
Verified March 2010 by University of Dundee.
Recruitment status was:  Active, not recruiting
First Posted : March 5, 2010
Last Update Posted : June 25, 2010
Sponsor:
Collaborator:
NHS Tayside
Information provided by:
University of Dundee

March 4, 2010
March 5, 2010
June 25, 2010
March 2010
March 2011   (Final data collection date for primary outcome measure)
  • Bleeding Complication [ Time Frame: 10 years ]
    Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.
  • Cardiovascular outcome [ Time Frame: 10 years ]
    Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event
Same as current
Complete list of historical versions of study NCT01081327 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Warfarin - How Good Are we at Maintaining Target Range ?
Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.
Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.
Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
All patients receiving Warfarin for lone atrial fibrillation
Atrial Fibrillation
Not Provided
Patients receiving Warfarin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
5000
Same as current
March 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prescription for Warfarin
  • Atrial Fibrillation

Exclusion Criteria:

  • Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma.
  • Conditions with increased risk of bleeding.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01081327
ELD007
No
Not Provided
Not Provided
Dr. Douglas Elder, University of Dundee
University of Dundee
NHS Tayside
Not Provided
University of Dundee
March 2010